Rothschedl, E. (2018): Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 84.

Wolf, S. and Wild, C. (2018): Drug reimbursement in the inpatient sector in Austria: Approaches for a transparent and evidence-based process, taking into account international experience . HTA-Projektbericht 109.

Reinsperger, I. and Goetz, G. and Winkler, R. (2018): Screening and prevention programmes for children and adolescents from 6 to 14 years. Results from selected countries and recommendations from evidence-based guidelines. HTA-Projektbericht 106.

McGahan , L (2018): Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström’s macroglobulinaemia. DSD: Horizon Scanning in Oncology 85.

Rosian, K. and Fischer, S. and Grössmann, N. (2018): Inhalation sedation with laughing gas (N2O) in dentistry – organisational and professional aspects and a systematic review of efficacy and safety. HTA-Projektbericht 105.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 37th Prioritization – 4th quarter 2018. HSO: 37th Prioritisation.

Zechmeister-Koss , I. and Goodyear, M. (2018): Supporting children who have parents with mental disorders in Tyrol: A mapping of existing Tyrolean support and societal structures. HTA-Projektbericht 113a.

Zechmeister-Koss, I. and Tüchler, H. (2018): Prevalence of mental disorders and uptake of mental health services in Tyrol: An analysis of epidemiological literature and administrative data from the Tyrolean health insurance. HTA-Projektbericht 113b.

Fuchs, S. and Grössmann, N. and Eckhardt, H. and Busse, R. and Wild, C. (2018): PET/PET-CT Evidence for need based planning in Germany and Austria. HTA-Projektbericht 77/ Update 2018.

Goetz, G. and Mitic, M. (2018): Carbon ion beam radiotherapy (CIRT) for cancer treatment: a systematic review of effectiveness and safety for 12 oncologic indications. HTA-Projektbericht 101.

Rothschedl, E. (2018): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC. DSD: Horizon Scanning in Oncology 82.

McGahan, L. (2018): Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 83.

Stanak, M. and Wolf, S. and Jagoš, H. (2018): External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine. Decision Support Document 114.

Reinsperger, I. and Rosian, K. and Winkler, R. and Piso, B. (2018): Re-orientation of the Austrian parent-child preventive care programme. Part XI: Further development of the mother-child-pass: Screening recommendations of the expert working group for pregnancy, puerperium and early childhood (0-6 years). HTA-Projektbericht 92.

Schmidt, L. and Lohr, P. and Wild, C. (2018): Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer. HTA-Projektbericht 107.

Winkler, R. (2018): Dropouts in Psychotherapy. Part I: Predictors, theories and models to explain and recommend courses of action to avoid discontinuation of therapy. Part II: "Overview of Reviews" on dropouts in psychotherapy. HTA-Projektbericht 100.

McGahan, L. (2018): Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non–small-cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 80.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 36th Prioritisation – 3rd quarter 2018. HSO: 36th Prioritisation.

Rothschedl, E. (2018): Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma. DSD: Horizon Scanning in Oncology 81.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 35th Prioritisation – 2nd quarter 2018. HSO: 35th Prioritisation.

Emprechtinger, R. (2018): Echocardiography: Guideline recommendations and options to identify inappropriate use as well as usage rate in Austria. HTA-Projektbericht 98.

Hawlik, K. and Winkler, R. (2018): Baroreceptor activation therapy for treatment-resistant hypertension. Decision Support Document 113.

Vreugdenburg, T. and Fischer, S. (2018): Meniscal allograft transplantation for post-meniscectomy syndrome. Decision Support Document 112.

Wagner, G. and Glechner, A. (2018): Subcutaneous implantable cardioverter defibrillator (ICD). Decision Support Document 109.

Erdos, J. and Fischer, S. (2018): High-intensity focused ultrasound for the treatment of prostate cancer. 1st Update 2018. Decision Support Document 37/ Update 2018.

Rosian, K. and Stanak, M. (2018): Lymphovenous anastomoses in patients with primary and secondary lymphoedema. Decision Support Document 110.

Wolf, S. and Stanak, M. (2018): Allogeneic mesenchymal stem cells for Crohn’s disease-associated complex perianal fistulas. Decision Support Document 111.

Wild, C. (2018): Endobronchial valve implantation for emphysema. Update 2018. Decision Support Document 20/ Update 2018.

Semlitsch, T. and Krenn, C. (2018): (Percutaneous) left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation. 3rd Update 2018. Decision Support Document 44/ Update 2018.

Rothschedl, E. (2018): Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL). DSD: Horizon Scanning in Oncology 79.

McGahan, L. (2018): Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC). DSD: Horizon Scanning in Oncology 78.

Dental and Pharmaceutical Benefits Agency (TLV), EUnetHTA and Main Association of Austrian Social Security Institutions (HVB), EUnetHTA and Agency for Quality and Accreditation in Health Care and Social Welfare (AAZ), EUnetHTA (2018): Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). EUnetHTA report. DSD: Horizon Scanning in Oncology 77.

Grössmann, N. and Wolf, S. (2018): Horizon Scanning in Oncology 34th Prioritisation – 1st quarter 2018. HSO: 34th Prioritisation.

Wild, C. and Blagojevic, S. and Petersen, P. (2018): Annual Report 2017.

Zorginstituut Nederland (ZIN), EUnetHTA and Belgian Health Care Knowledge Centre (KCE), EUnetHTA (2018): MammaPrint® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer. EUnetHTA report . HTA-Projektbericht 102.

Galician Agency for Health Technology Assessment (avalia-t), EUnetHTA and Regione Emilia Romagna (RER), EUnetHTA (2018): Screening for fetal trisomies 21, 18 and 13 by non-invasive prenatal testing (NIPT). EUnetHTA-Report. HTA-Projektbericht 103.